To meet the rapidly increasing need for COVID-19 research tools, NBS-C BioScience has established an interdisciplinary SARS-CoV-2 SPR platform which addresses the molecular and functional characterization of drug - target interactions under investigation in SARS-CoV-2 related R&D projects as well as qualitative and quantitative analysis of polyclonal antibody responses to SARS-CoV-2 infection and vaccine candidates.
The SARS-CoV-2 viral genome encodes 29 proteins:
• 4 structural proteins (S, E, M, N)
• 16 non-structural proteins (Nsp1-16)
• 9 accesscory factors (Orf3a, Orf3b, Orf6, Orf7a, Orf7b, Orf8, Orf9b, Orf9c, Orf10)
Our SPR platform provides insight into how biologic molecules, chemical drugs or antibodies induced by vaccines or SARS-CoV-2 infection interact with viral proteins. Thus, the platform represents a versatile tool box for various applications in pre-clinical, clinical and pharmaceutical COVID-19 R&D. We measure binding specificity, kinetics / affinities and biological (neutralizing) potency for a variety of relevant SARS-CoV-2 derived molecular targets, including continuously emerging mutant virus variants. The panel of target proteins is regularly adapted to knowledge gained from most recent SARS-CoV-2 / COVID-19 research and can be customized according to individual client’s demands.
APPLYING OUR ESTABLISHED SARS-CoV-2 / COVID-19 SPR PLATFORM WE STUDY THE INTERACTION OF TARGET MOLECULES INVOLVED IN VIRAL PATHOMECHANISM AND DISEASE PROTECTION FOR CLIENTS WORKING ON